Omexta

Essential HTN.

Adult Initially 20 mg once daily. If required, may be increased to 40 mg once daily or add hydrochlorothiazide. Elderly, mild to moderate renal impairment (CrCl 20-60 mL/min) Max dose: 20 mg once daily.

May be taken with or without food: Take at about the same time each day.

Hypersensitivity. Patients w/ biliary obstruction. Concomitant use w/ aliskiren in patients w/ DM. 2nd & 3rd trimesters of pregnancy & lactation.

Discontinue use if symptoms of sprue-like enteropathy develop during treatment. Not recommended in patients w/ primary aldosteronism. Symptomatic hypotension in patients whom intravascular vol or salt are depleted (eg, those treated w/ diuretics, dietary salt restriction, diarrhea, or vomiting). Patients w/ unilateral/bilateral renal artery stenosis; significant aortic/mitral stenosis or obstructive hypertropic cardiomyopathy; ischemic heart disease or cerebrovascular disease. Hyperkalemia. Black patients. Periodically monitor serum K & creatinine levels; serum electrolytes; renal function in patients receiving concomitant therapy w/ NSAIDs including selective COX-2 inhibitors. Administer treatment at least 4 hr prior to colesevelam. Not recommended in combination w/ lithium. May deteriorate renal function. Not recommended in patients w/ severe renal impairment (CrCl <20 mL/min), hepatic impairment. May increase risk of major congenital malformations during 1st trimester of pregnancy. Discontinue lactation during treatment. Childn & adolescents up to 18 yr.

Dizziness, headache, vertigo; nausea, vomiting, diarrhea, abdominal pain, dyspepsia, gastroenteritis, sprue-like enteropathy; cough, bronchitis, pharyngitis, rhinitis; haematuria, UTI, acute renal failure, renal insufficiency; arthritis, back pain, muscle spasm, myalgia, bone pain; pruritus, rash, exanthematous rashes, allergic conditions eg, allergic dermatitis, angioedema, facial edema & urticaria; chest pain, flu-like symptoms, peripheral edema, pain, asthenic conditions eg, asthenia, fatigue, lethargy, malaise; increased creatine phosphokinase, liver enzyme elevations, abnormal renal function tests eg, increased blood creatinine & blood urea; hypertriglyceridemia, hyperuricemia, hyperkalemia; anaphylactic reaction; hypotension, angina pectoris; thrombocytopenia.

Concomitant use w/ ACE inhibitors, angiotensin II receptor antagonists, aliskiren; NSAIDs, including selective COX-2 inhibitors. Decreased systemic exposure & peak plasma conc w/ colesevelam HCl. Increased serum lithium conc.

Angiotensin II Antagonists

C09CA08 - olmesartan medoxomil ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

D